Background: It is unclear whether the combination of adalimumab (ADA) and immunomodulators is superior to ADA monotherapy in patients with
C
rohn's disease (CD) is a chronic disorder of the gastrointestinal tract characterized by remitting and relapsing inflammation often associated with extraluminal complications, and that may lead to irreversible bowel damage. Considerable advances in the treatment of moderate-to-severe CD were achieved in the last 2 decades after the introduction of biological therapy, namely anti-tumor necrosis factor (TNF) inhibitors, resulting in improved clinical outcomes with reduction in morbidity, disease-related hospitalizations, and surgery. 1, 2 However, 10% to 30% of patients have primary nonresponse to these agents 3, 4 and a significant number (estimated at 13%-24% per year) lose response over time. 5, 6 To optimize response to antiTNFs, the use of concomitant immunomodulators (IMMs) has been advocated for its potential to augment clinical benefit by targeting a different mechanism of inflammation independent of the TNF pathway. When added to infliximab (IFX), IMMs were found to reduce immunogenicity and rates of infusion reactions, increase serum levels of IFX, and reduce inflammatory markers and possibly disease flares. 7, 8 In a randomized controlled trial (SONIC), combination therapy of IFX and azathioprine was shown to be superior to monotherapy with either IFX or azathioprine in patients with moderate-to-severe early CD (median duration of disease was 2.2 years) naive to both IMMs and biologics. 9 At week 26, more patients achieved remission in the combination group than the IFX group (risk of failure to achieve remission compared with IFX: RR 0.78; 95% confidence interval [CI] , 0.62-0.97). 10 However, a recent subgroup analysis of the SONIC study suggested that the benefit of combination therapy is primarily a result of reduced immunogenicity and improved IFX blood levels. 11 Whether the addition of IMMs to all anti-TNFs results in superior clinical outcomes remains an issue of intense debate. The latest ECCO guidelines state that it is unknown whether combination therapy with anti-TNF agents other than IFX improves outcome in patients naive to immunosuppressives other than steroids. 12 Studies on adalimumab (ADA), a fully human monoclonal antibody with significantly less immunogenicity that IFX 13 have reported mixed results regarding benefit of combination therapy. 9 A recent retrospective analysis of 521 anti-TNFnaive patients on ADA showed significantly better response rates with combination therapy, with more than 20% better response at 6 months and 2 years compared with monotherapy. 14 A metaanalysis published in 2014 suggested a mild superiority of ADA combination therapy in CD only for the induction of remission, but a definite recommendation was limited by the lack of randomized control trials (RCTs) on that topic. 15 Since then, at least 7 new studies containing comparisons between ADA monotherapy and combination therapy have been published including one recent randomized open-label trial in anti-TNF-naive and IMMnaive patients. In that study (DIAMOND), there was no significant advantage of combination therapy over monotherapy in terms of remission. 16 Better endoscopic response was seen in the combination arm at 26 weeks, but results at 52 weeks were not different between ADA combination therapy with azathioprine and monotherapy. 16 Given the controversial evidence, this metaanalysis was undertaken to compare the efficacy of ADA monotherapy versus combination therapy with IMMs in inducing and maintaining remission and response in patients with CD.
METHODS

Inclusion and Exclusion Criteria
Prospective RCTs, retrospective cohort studies, open-label, cross-sectional, and pooled studies that compared ADA monotherapy and combination therapy with IMMs were included in this meta-analysis. Comparisons of rates of induction of remission and response, maintenance of remission and response, rates of adverse events (AEs) rate and of opportunistic infections, as well as the rate of development of antibodies to adalimumab (ATA) were among the outcomes of the selected studies. Studies including a stratified comparison of any of the above outcomes were included. Excluded studies included those published only in abstract form, pediatric-age studies, and those that exclusively assessed postsurgical outcomes, or did not include any of the outcomes of interest.
Search Strategy and Data Sources
We searched electronic database through PubMed, Medline (through OVID), Embase, Web of Science, and the Cochrane Controlled Trials Register for literature since initiation until February 7, 2017 without any language restrictions. Search keywords included "Crohn's disease," "adalimumab," "therapy," "azathioprine," "6-mercaptopurine (6-MP)" "mercaptopurine," "methotrexate," and "immunomodulators," as MeSH and free text terms, and root variations of these keywords were used in an attempt to improve search outcomes. Our search strategy included broad keywords, as most targeted studies did not have our outcome of interest as their primary outcome. In addition, we performed a thorough search for abstracts from different international gastroenterology conferences (Digestive Disease Week, American College of Gastroenterology conference, United European Gastroenterology Week, European Crohn's and Colitis annual conference, Crohn's and Colitis Foundation of America Advances in IBD meeting, and the Asia-Pacific Digestive Week), clinical trials database (www. clinicaltrials.gov), and gastroenterology journals in an attempt to retrieve more articles. With the intention to identify additional trials, the references of all articles were manually reviewed and identified. All searches were limited to studies on adult humans.
Study Outcomes
The primary aim of our study was to compare the efficacy of ADA monotherapy to that of ADA combination therapy with IMMs in inducing and maintaining remission and response. Induction of clinical remission is assessed based on a Crohn's disease activity index (CDAI) ,150 or a Harvey Bradshaw Index (HBI ,4) after #12 weeks. Induction of response was defined as a DCDAI .70 or a DHBI .2 after #12 weeks. In cases where a subjective score was not available, response was assessed based on the physician's global assessment or according to mucosal healing on endoscopy. Maintenance of remission and response was assessed after #56 weeks of therapy. Secondary outcomes of the study included a comparison of the rate of serious/severe AEs, the rate of opportunistic infections, and the development of ATA with ADA monotherapy versus combination therapy.
Study Selection
Two investigators (J.M.C. and H.H.R.) independently assessed the titles and abstracts of all retrieved papers and reviewed their eligibility for inclusion in our meta-analysis. Investigators independently collected study characteristics in standardized data sheets after full-text assessment and consensually decided on including or excluding selected studies. The principal investigator (A.I.S.) addressed discrepancies, and thus made the final decision to whether include or exclude a study. This article follows the PRISMA agreement reporting guidelines, and the flow diagram for study selection is summarized in Figure 1 .
Data Extraction
Full-text reviews of the 24 selected studies were done. Characteristics of the studies (first author, year of publication, study design, number of participants, inclusion criteria, and outcomes of interest) were extracted after identifying all relevant articles. One investigator (J.M.C.) performed data abstraction and assessed outcomes mainly including the induction of remission and response, maintenance of remission and response, severe AE rate, the rate of opportunistic infection, and the rate of developing ATA. Retrieved data were thoroughly reviewed by the principal investigator who approved its inclusion as is.
Statistical Analysis
In this meta-analysis, we followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) criteria. 17 Analysis was performed using Review Manager (The Cochrane Collaboration, Oxford, UK), and odds ratios (ORs) with 95% CIs were evaluated for the quantitative analyses of all outcomes. The x 2 test and I 2 statistic were used to assess statistical heterogeneity among trials. The I 2 statistic reflects the percentage of variation between studies because of heterogeneity rather than chance only with values ranging from 0% (no heterogeneity) to 100% (maximal heterogeneity). An I 2 . 50% and a P value ,0.1 for the x 2 were considered a marker of significant heterogeneity.
We planned subgroup and sensitivity analysis in advance and used the random-effects method for conducting this metaanalysis. Subgroup analyses were performed for all primary outcomes based on the following criteria: (1) studies evaluating induction of remission and response at ,12 weeks versus those evaluating at 12 weeks, (2) studies evaluating maintenance of remission and response at ,52 weeks versus those evaluating at $52 weeks, (3) studies with #200 patients on ADA versus those with .200 patients on ADA, (4) studies on anti-TNF-naive patients versus studies on TNF-naive and TNF-exposed patients, (5) studies on patients with moderate-to-severe CD versus studies in patients with active CD regardless of severity, (6) randomized versus nonrandomized studies, and (7) prospective versus retrospective studies. Quality and trial bias risk assessments were assessed using RevMan for RCTs. Alternatively, non-RCT cohorts were assessed using the Newcastle-Ottawa scale. 18 Sensitivity analysis was done by stratifying studies with unclear or high risk of any type of bias versus studies with low risk of bias, regardless of study design. We also assessed for possible publication bias by creating an inverted funnel plot for the primary outcome.
RESULTS
Literature Search
The initial search of the abovementioned databases yielded a total of 1591 hits of which, 397 were duplicates. As a result, 1194 articles were screened, with a remainder of 268 studies assessed for eligibility by full-text review. A total of 244 studies were excluded as they were either only published as abstract (n ¼ 42), did not assess outcomes of interest of this meta-analysis (n ¼ 91), only evaluated postsurgical patients (n ¼ 46), had a target pediatric population (n ¼ 49), or did not provide a response about outcomes of interest when contacted (n ¼ 11). One crosssectional study was excluded because of methodological limitations (n ¼ 1). Twenty-four remaining studies were included in this meta-analysis. A summary of the study selection process is available in Figure 1 .
Characteristics of Selected Trials
Included studies differed in designs, inclusion criteria, primary outcomes, and definitions of outcomes of interest. Our meta-analysis consisted of 6 double-blinded RCTs, 3 open-label trials (one of which was randomized), 6 prospective cohort studies, 8 retrospective studies, and 1 pooled analysis study. In addition, 11 studies only included patients with severe to moderate CD, whereas 6 studies only included anti-TNF-naive patients and 4 studies included patients who failed IFX. Follow-up intervals varied between studies, ranging from 4 to 12 weeks for induction and from 24 to 56 weeks for maintenance of remission and response. A comparison between monotherapy and combination therapy was not initially assessed by all the included studies and for that reason, we checked all supplemental material when available and contacted authors to provide further pertinent data. Our assessment of the included RCTs for possible bias yielded a higher risk of attrition bias in 2 of the 6 studies (,35%) (see Figure Outcome bias based on accuracy and duration of follow-up could exclusively be detected in 2 studies. Comparability bias, which is minimized by matching study patients or by adjusting for confounders in data analysis, was evident in 9 studies of which 4 also had a component of outcome bias. A low risk (,25%) of selection, detection, performance, and reporting bias was found in the studies. Overall, 13 of the 25 studies had at least one type of bias, and consequently, we performed our sensitivity analysis based on outcome bias, comparability bias, attrition bias, or the presence of any type of bias. Visual inspection of the inverted funnel plot does not suggest the presence of a publication bias (see Fig, Supplementary Digital Content 1, http://links.lww.com/IBD/B566). The characteristics of the selected studies are summarized in Table 1 .
Primary Outcomes
Induction of Remission
The effect of monotherapy versus combination therapy in inducing remission between weeks 4 and 12 was evaluated by 11 studies, compiling a total of 3096 patients including 1400 on combination therapy. Data analysis using the random-effects model did not show any statistically significant difference between monotherapy and combination therapy in inducing remission (odds ratio [OR] 0.86; 95% CI [0.70-1.06]) ( Fig. 2A) . Heterogeneity was not significant with an I 2 of 26% and a P value of 0.17. Among other subgroup analyses mentioned above (see . anti-TNF naivety as a criterion for inclusion, the lack of patient randomization, and retrospective study type, showed statistical difference. In anti-TNF-naive patients, combination therapy was not favorable compared with monotherapy. However, in studies including anti-TNF-exposed patients, combination treatment had 1. 
Induction of Response
No significant statistical difference between monotherapy and combination therapy was obtained concerning response rates (OR 1.01; 95% CI [0.62-1.65]) (Fig. 2B) . Unlike the induction of remission, induction of response was only assessed by 7 studies with a total of 1040 patients, including 477 individuals on combination therapy. Those studies also happened to have significant heterogeneity reflected by an I 2 of 51% and a P value of 0.06. This can be attributed to the difference in study designs and different overall study outcomes. Subgroup (see Supplemental Digital Content 9-14, http://links.lww.com/IBD/B574, http://links.lww.com/ IBD/B575, http://links.lww.com/IBD/B576, http://links.lww.com/ IBD/B577, http://links.lww.com/IBD/B578, and http://links.lww. com/IBD/B579) and sensitivity analysis based on the risk of bias also failed to show any significant difference between the 2 study groups (see Fig, Supplementary Digital Content 15 , http://links. lww.com/IBD/B580). To adjust for the high heterogeneity, we ran another sensitivity analysis excluding the study by Sprakes et al, 19 which only included 44 patients in whom response was assessed after 6 weeks. A nonsignificant heterogeneity was obtained (I 2 ¼ 41%; P value ¼ 0.13) along with a lack of statistical difference between monotherapy and combination therapy in terms of response (OR 1. 
Maintenance of Remission
A total of 1885 patients (859 on combination therapy) were available for analysis from 9 studies. Analysis through the random-effects model showed no difference between users of both monotherapy and combination therapy (OR 0.97; 95% CI [0.79-1.14]) (Fig. 3A) . Heterogeneity was again nonsignificant (I 2 ¼ 0%; P value ¼ 0.63), and subgroup 
Maintenance of Response
Analysis of 1735 cases studied for maintenance of response up to 52 weeks yielded no difference in outcome between patients on monotherapy compared with combination therapy (OR 0.91; 95% CI [0.54-1.54]) (Fig. 3B) . A significant statistical heterogeneity was found with an I 2 of 80% and a P value ,0.0001. To decrease heterogeneity among studies, we performed a sensitivity analysis excluding the study by Cosnes et al that showed similar results with no significant heterogeneity (OR 1.09; 95% CI [0.84-1.40]; I 2 ¼ 0%; P value ¼ 0.58) (see 
Secondary Outcomes
Adverse Events
Concerning AEs, studies differed in their reporting ranging from minor skin reactions to opportunistic infections. In this evaluation of AE, we only included serious or severe AE as reported by studies, excluding opportunistic infections. Our analysis of 8 studies with a total of 3274 subjects (1531 on combination therapy) showed no significant difference in severe AE rate between monotherapy and combination therapy (OR 1.15; 95% CI [0.77-1.73]) with no significant heterogeneity (I 2 ¼ 39%; P value ¼ 0.12) (Fig. 4) . Subgroup analysis for prospective versus retrospective studies showed no difference between both study arms (see Fig, Supplementary Digital Content 32 , http:// links.lww.com/IBD/B597).
Opportunistic Infections
Six studies with a total of 1890 cases (843 on combination therapy) assessed the rate of opportunistic infections. Our metaanalysis failed to show any difference between the 2 study arms (OR 0.49; 95% CI [0.22-1.08]). No significant heterogeneity is reported in this analysis with an I 2 of 0% and a P value of 0.63 (Fig. 5A ). Only one study by Sprakes et al 19 favored combination therapy over monotherapy and only reported 2 cases (n ¼ 44) in the monotherapy group. Sensitivity analysis performed with the exclusion of this study, significantly favored monotherapy over (Fig. 5B) . There was no significant difference between monotherapy and combination therapy when prospective and retrospective subgroup analysis was done (see Fig, Supplementary Digital Content 33 , http:// links.lww.com/IBD/B598).
Antibodies to Adalimumab
Three studies with a total of 579 cases (245 on combination therapy) assessed the rate of development on ATA, but only 2 RCTs statistically contributed to the reported results, as the third study had no cases of ATA. Users of combination therapy had almost 4 times lesser odds of developing ATA compared with those on monotherapy (OR 0.24; 95% CI [0.07-0.82]). Heterogeneity was not statistically significant with an I 2 ¼ 0% and a P value of 0.67 (Fig. 6 ).
DISCUSSION
The results of this systematic review and meta-analysis suggest that there is no added benefit to the addition of IMMs to ADA in the induction of clinical remission and response and maintenance of medically induced remission in patients with CD. In fact, our analysis suggests a possible increased risk of opportunistic infections associated with the use of combination therapy. In 2014, a meta-analysis by Kopylov et al 15 addressing similar outcomes found a possible mild superiority of combination therapy in inducing remission only, with no other differences in terms of inducing response and maintaining remission or response. That meta-analysis, however, examined data from only 7 studies for the outcome of induction of remission. In our metaanalysis, we added 5 additional studies including 2 prospective randomized trials, 16, 20 and 2 prospective cohort studies resulting in a higher number of patients (3036 versus 665). 21, 22 Of note, among all 12 studies, only 3 were designed to compare the efficacy of monotherapy and combination therapy. 16, 23, 24 Alternatively, with the exception of the trial by Matsumoto et al which enrolled IMM-naive patients, 16 all included RCTs only compared ADA with placebo and were not intended to compare ADA monotherapy with combination therapy, effectively including patients with inadequate response to IMMs. Our sensitivity analysis shows no benefit in induction of response in randomized trials compared with a significant advantage of combination therapy in nonrandomized studies (Supplementary Digital Content 6, http:// links.lww.com/IBD/B571). It is important to note, however, that the latter group of studies are heterogeneous and cannot provide definitive evidence whether the noted benefit is with de novo combination therapy or with sequential IMMs/ADA in partial or complete nonresponders to previous therapy.
The results of our meta-analysis are aligned with those from another meta-analysis by Jones et al 25 in patients with luminal or fistulizing CD, nonnaive to anti-TNF and IMMs. That study suggested no benefit of combination therapy with any anti-TNF for inducing remission and response at 6 months, maintaining response, and improving fistula closure. 25 In our meta-analysis, the maintenance of remission between 24 and 56 weeks was not different between patients on monotherapy and those on combination therapy.
The SONIC trial confirmed the superiority of combination IFX and azathioprine over monotherapy in early CD. 9 Patients in the combination arm had reduced immunogenicity and higher plasma levels of IFX, which may have contributed to the clinical benefit. In fact, a recent post hoc analysis of SONIC found no consistent benefit in clinical efficacy with the addition of azathioprine to IFX leading the authors to posit that the benefit of combination therapy is primarily due to the influence of azathioprine on the pharmacokinetics on IFX. 11 It is unclear whether the addition of an IMM impacts the efficacy of a less immunogenic anti-TNF biologic such as ADA in CD. After a similar design to the SONIC trial, the recent DIAMOND study tried to address this question by enrolling patients with early CD naive to both anti-TNF and IMMs. 16 Patients were randomized to receive top-down strategy with either monotherapy or combination therapy. Given a relatively considerable rate of patient withdrawal from both study arms, nonresponder imputation analysis was done showing no significant difference between study arms in terms of induction of remission up to 26 weeks. The only difference was endoscopic improvement at 26 weeks favoring combination therapy (84% versus 64% with monotherapy). No difference in endoscopic improvement was observed at 52 weeks.
We found that combination therapy is associated with reduced immunogenicity leading to lower odds of developing ATA. Unlike IFX, the pharmacokinetics of ADA did not seem to be affected significantly by concomitant IMMs. In the CLASSIC I and II trials, the clearance and the mean steady-state ADA concentrations at week 24 were not significantly different in subjects on concomitant IMMs compared with those without. 26 Even though ADA is less immunogenic than IFX, it is conceivable that, as in SONIC, the effect on immunogenicity and pharmacokinetics underlies any potential benefit of combination therapy particularly in patients at risk of immunogenicity with ADA, namely immunized IFX-experienced patients. 27 In fact, when we performed a subgroup analysis according to anti-TNF naivety, combination therapy was associated with higher odds of induction of remission in studies including anti-TNF-exposed patients. Sensitivity analysis for the induction of remission was statistically significant, as 4 studies with possible risk of bias significantly favored combination therapy. None of these studies was, however, designed to directly compare monotherapy with combination therapy evidenced by the comparability bias present in all 4 studies. In addition, 2 of the studies had a component of outcome bias, further questioning the validity of the results. It is worth mentioning that 3 of the 4 studies with a relative high/ unclear risk of bias were included in the significant subgroup analysis on anti-TNF naivety, casting doubt on the significance of those results. In addition, the significant subgroup analyses based on study types and designs significantly favored combination therapy over monotherapy in nonrandomized and retrospective studies. This goes hand in hand with the abovementioned sensitivity analysis, as studies with higher risk of bias were nonrandomized and/or retrospective studies. Lastly, it is a common practice to treat patients with previous anti-TNF failure and moderate-to-severe disease with combination therapy, and whether the above-noted benefit is related to a direct effect of the IMMs on the disease or simply to reduced immunogenicity and/or recapture of response is unclear. 28, 29 As expected, studies included in our meta-analysis did not have similar methodologies partly accounting for the observed heterogeneity. For induction of response, results before and after sensitivity analysis adjusting for heterogeneity showed no difference between the 2 study arms. The study by Sprakes et al 19 was excluded as an outlier in the sensitivity analysis particularly given its small sample size. On the other hand, the study by Cosnes et al 14 clearly favored combination therapy over monotherapy in terms of response after 26 weeks. As a result, outcomes were skewed and heterogeneity was significant, but that was adjusted after sensitivity analysis excluding this study. Despite no change in results before and after sensitivity analysis, it is important to note that data drawn by Cosnes et al are based on the number of exposures, thus possibly leading to redundancy of failed cases. In other words, patients failing an initial exposure to medications are more likely to be re-exposed to treatment. This and the lack of data on dose escalation make the external validity of their results questionable.
Comparing the rate of adverse effects between both arms proved challenging, as the range of reported AEs varied between studies from mild skin reactions to opportunistic infections and associated mortalities. We focused on clinically significant AE by including only severe or serious AE. Taken into consideration the limited duration of follow-up, there was no significant difference between study arms. However, after sensitivity analysis, combination therapy had 2.4 times significantly higher odds of opportunistic infections compared with monotherapy. In a pooled analysis by Osterman et al 30 , combination therapy users were found to be at increased risk of malignancy compared with patients on ADA monotherapy who had a similar risk to that of the general population. Although such serious AE might be expected with increased immunosuppression, their overall frequency with combination therapy remains low (malignancy: ,1 event/100 person-year 30 ; opportunistic infections: ,2% pooled frequency of events in studies included in our analysis).
The methodological variations between the included studies represent one of the limitations of our meta-analysis. Of the 25 studies included, only 5 directly evaluated different outcomes in patients on monotherapy versus combination therapy, 14, 16, 23, 24, 30 including only one randomized prospective trial. 16 The remaining studies did not compare all outcomes of interest between monotherapy and combination therapy users; as a result, data were obtained by author contact. When RCTs were concerned, patients were randomized on criteria other than treatment modality, and thus several confounders could not be accounted for. Important confounders include the type of IMMs and the duration of exposure, smoking status, disease location, anti-TNF and IMM naivety before therapy, failure of previous anti-TNF treatment, steroid use, history of CD-related surgery, and smoking status. Preplanned subgroup analyses based on disease status and naivety to anti-TNF remain suboptimal compared with in-study randomization to control for confounders. Furthermore, in clinical settings, patients with severe disease or with failure of previous treatments tend to receive combination therapy. As a result, the lack of patient segregation according to clinical severity, failure of response to previous IMMs or anti-TNF, or other confounders probably masked the detection of a possible benefit from combination therapy in certain populations. In addition, definitions of concomitant therapy were different between the various studies ranging from IMM use up to 12 weeks before ADA use, to IMM initiation months after the start of ADA therapy. In this metaanalysis, we did not include dose escalation as one of the outcomes of interest, as we were unable to obtain any pertinent data from new studies, and most data remain unchanged from the meta-analysis by Kopylov et al 15 with no significant difference between the 2 regimens.
In conclusion, this meta-analysis suggests no clear added benefit from combination therapy of ADA with IMMs compared with ADA monotherapy for the induction and maintenance of remission and response in CD. The small number of randomized trials addressing this particular question and the heterogeneity of some studies in terms of IMM exposure (before, with, or after ADA) are important limitations. However, subgroup analyses of studies including anti-TNF-experienced patients highlight the need for further studies to explore any advantage of combination therapy including dose, duration, use in patients at high risk for disabling disease course, or in those at risk for immunogenicity as well as strategies for de-escalation in light of the increased risk of malignancies and possibly of opportunistic infections.
